奥美拉唑联合双歧杆菌三联活菌肠溶胶囊治疗急性胃肠炎的效果观察

Observation on the Efficacy of Omeprazole Combined with Bifidobacterium Triple Viable Enteric Coated Capsules in the Treatment of Acute Gastroenteritis

为分析将奥美拉唑联合双歧杆菌三联活菌肠溶胶囊用于急性胃肠炎治疗中的临床价值,选取2022年1月—2022年12月瓮安县妇幼保健院收治的88例急性胃肠炎患者作为研究对象,按照随机数字表法将其平均分为对照组和观察组,每组各44例。对照组实施奥美拉唑治疗,观察组实施奥美拉唑+双歧杆菌三联活菌肠溶胶囊治疗。对比两组患者治疗效果、症状改善用时、炎症因子水平、肠道菌群及不良反应发生情况。结果显示,观察组患者治疗总有效率高于对照组(P<0.05);观察组患者症状改善用时均短于对照组(P<0.05);治疗后,观察组患者炎症因子水平均低于对照组(P<0.05);治疗后,观察组患者肠道菌群数量均高于对照组(P<0.05)。研究发现,将奥美拉唑+双歧杆菌三联活菌肠溶胶囊用于急性胃肠炎治疗中效果显著,可缩短患者症状改善时间,降低患者机体炎症因子水平,调节其肠道菌群,且用药不良反应少,安全性高,可推广应用。

To analyze the clinical value of omeprazole combined with bifidobacterium triple viable enteric coated capsules in the treatment of acute gastroenteritis,88 patients with acute gastroenteritis admitted to Weng’an Maternal and Child Health Hospital from January 2022 to December 2022 were selected as the study subjects.They were evenly divided into two groups according to random number table method,namely the control group and the observation group,with 44 cases in each group.The control group received omeprazole treatment,while the observation group received omeprazole+bifidobacterium triple viable enteric coated capsules.Compare the treatment effectiveness,symptom improvement time,inflammatory factor levels,intestinal microbiota,and incidence of adverse reactions between the two groups of patients.The results showed that the total effective rate of treatment in the observation group was higher than that in the control group,with a statistically significant difference(P<0.05);The symptom improvement time of the observation group patients was shorter than that of the control group.After treatment,the levels of inflammatory factors in the observation group were lower than those in the control group,with a statistically significant difference(P<0.05).Research has found that the use of omeprazole+bifidobacterium triple viable enteric coated capsules in the treatment of acute gastroenteritis has a significant effect,can accelerate the time for symptom improvement,reduce the level of inflammatory factors in the patient’s body,regulate their intestinal microbiota,and has fewer adverse reactions and high safety,which can be promoted and applied.